Alhamdi Yasir, Neill Daniel R, Abrams Simon T, Malak Hesham A, Yahya Reham, Barrett-Jolley Richard, Wang Guozheng, Kadioglu Aras, Toh Cheng-Hock
Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Department of Musculoskeletal Biology, Institute of Aging and Chronic Diseases, University of Liverpool, Liverpool, United Kingdom.
PLoS Pathog. 2015 May 14;11(5):e1004836. doi: 10.1371/journal.ppat.1004836. eCollection 2015 May.
Streptococcus pneumoniae accounts for more deaths worldwide than any other single pathogen through diverse disease manifestations including pneumonia, sepsis and meningitis. Life-threatening acute cardiac complications are more common in pneumococcal infection compared to other bacterial infections. Distinctively, these arise despite effective antibiotic therapy. Here, we describe a novel mechanism of myocardial injury, which is triggered and sustained by circulating pneumolysin (PLY). Using a mouse model of invasive pneumococcal disease (IPD), we demonstrate that wild type PLY-expressing pneumococci but not PLY-deficient mutants induced elevation of circulating cardiac troponins (cTns), well-recognized biomarkers of cardiac injury. Furthermore, elevated cTn levels linearly correlated with pneumococcal blood counts (r=0.688, p=0.001) and levels were significantly higher in non-surviving than in surviving mice. These cTn levels were significantly reduced by administration of PLY-sequestering liposomes. Intravenous injection of purified PLY, but not a non-pore forming mutant (PdB), induced substantial increase in cardiac troponins to suggest that the pore-forming activity of circulating PLY is essential for myocardial injury in vivo. Purified PLY and PLY-expressing pneumococci also caused myocardial inflammatory changes but apoptosis was not detected. Exposure of cultured cardiomyocytes to PLY-expressing pneumococci caused dose-dependent cardiomyocyte contractile dysfunction and death, which was exacerbated by further PLY release following antibiotic treatment. We found that high PLY doses induced extensive cardiomyocyte lysis, but more interestingly, sub-lytic PLY concentrations triggered profound calcium influx and overload with subsequent membrane depolarization and progressive reduction in intracellular calcium transient amplitude, a key determinant of contractile force. This was coupled to activation of signalling pathways commonly associated with cardiac dysfunction in clinical and experimental sepsis and ultimately resulted in depressed cardiomyocyte contractile performance along with rhythm disturbance. Our study proposes a detailed molecular mechanism of pneumococcal toxin-induced cardiac injury and highlights the major translational potential of targeting circulating PLY to protect against cardiac complications during pneumococcal infections.
在全球范围内,肺炎链球菌通过包括肺炎、败血症和脑膜炎在内的多种疾病表现形式,导致的死亡人数比任何其他单一病原体都多。与其他细菌感染相比,危及生命的急性心脏并发症在肺炎球菌感染中更为常见。值得注意的是,尽管进行了有效的抗生素治疗,这些并发症仍会出现。在这里,我们描述了一种心肌损伤的新机制,该机制由循环中的肺炎溶血素(PLY)触发并持续存在。使用侵袭性肺炎球菌疾病(IPD)的小鼠模型,我们证明表达野生型PLY的肺炎球菌而非PLY缺陷型突变体可诱导循环心肌肌钙蛋白(cTn)升高,cTn是公认的心脏损伤生物标志物。此外,cTn水平升高与肺炎球菌血计数呈线性相关(r = 0.688,p = 0.001),且非存活小鼠的水平显著高于存活小鼠。通过给予PLY螯合脂质体,这些cTn水平显著降低。静脉注射纯化的PLY,但非形成孔道的突变体(PdB),可诱导心肌肌钙蛋白大幅增加,这表明循环PLY的孔道形成活性对于体内心肌损伤至关重要。纯化的PLY和表达PLY的肺炎球菌也会引起心肌炎症变化,但未检测到细胞凋亡。将培养的心肌细胞暴露于表达PLY的肺炎球菌会导致剂量依赖性的心肌细胞收缩功能障碍和死亡,抗生素治疗后PLY的进一步释放会加剧这种情况。我们发现高剂量的PLY会诱导广泛的心肌细胞溶解,但更有趣的是,亚溶解浓度的PLY会引发大量钙内流和过载,随后导致膜去极化以及细胞内钙瞬变幅度逐渐降低,而细胞内钙瞬变幅度是收缩力的关键决定因素。这与临床和实验性败血症中通常与心脏功能障碍相关的信号通路激活相关联,最终导致心肌细胞收缩性能下降以及节律紊乱。我们的研究提出了肺炎球菌毒素诱导心脏损伤的详细分子机制,并强调了靶向循环PLY以预防肺炎球菌感染期间心脏并发症的主要转化潜力。